Erysipelas after breast cancer treatment (26 cases)

• Published in: Dermatology online journal Vol. 11; no. 3; p. 12
• Main Authors: Masmoudi, A, Maaloul, I, Turki, H, Elloumi, Y, Marrekchi, S, Bouassida, S, Ben Jemaa, M, Zahaf, A
• Format: Journal Article
• Language: English
• Published: United States 2005
• Subjects: Adult; Aged; Aged, 80 and over; Breast Neoplasms - therapy; Erysipelas - epidemiology; Erysipelas - etiology; Female; Humans; Middle Aged; Retrospective Studies
• ISSN: 1087-2108; 1087-2108
• DOI: 10.5070/D35TK050BW

Erysipelas is a bacterial hypodermal cellulitis usually associated with Streptococcal infection. Erysipelas of the upper limbs in women treated for breast cancer is relatively rare. We undertook a 10-year retrospective study identifying 26 cases of erysipelas of the upper limb following treatment for breast cancer; we describe the clinical, therapeutic, and evolutionary aspects. The age of our patients ranged from 37 to 80 years with a mean age of 53. All patients had a breast surgery and lymphadenectomy. Fifteen patients had chemotherapy and 23 had radiotherapy. The erysipelas appeared with an average of 5.23 years after cancer treatment (3 months to 15 years) and was recurrent in nine cases. Lymphedema occurred in eighteen patients. The first signs were fever and shivering in 25 patients. The clinical aspect was an inflammatory plaque. The physical findings of erysipelas included a raised edge (6 cases), blisters (1 case), purpura (1 case), and cellulitis (1 case). The portal of entry was not found in eleven patients. The upper limb was affected in all cases. Involvement of the axillary folds or the chest was observed in eight cases. Treatment with penicillin was undertaken for all patients; the length of treatment varied from 11 to 26 days. Lympadenectomy and radiotherapy in breast cancer may lead to lymphedema, which can be evident or sometimes discrete. Those patients who developed erysipelas in our series usually fared well with treatment, but many had recurrences attributed to persistent lymphedema. It was also of note that for many patients in this series, the portal of entry was not identified.